BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sridhar S, Greenwood B, Head C, Plotkin SA, Sáfadi MA, Saha S, Taha MK, Tomori O, Gessner BD. Global incidence of serogroup B invasive meningococcal disease: a systematic review. Lancet Infect Dis 2015;15:1334-46. [PMID: 26453240 DOI: 10.1016/S1473-3099(15)00217-0] [Cited by in Crossref: 49] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Badur S, Khalaf M, Öztürk S, Al-Raddadi R, Amir A, Farahat F, Shibl A. Meningococcal Disease and Immunization Activities in Hajj and Umrah Pilgrimage: a review. Infect Dis Ther 2022. [PMID: 35585384 DOI: 10.1007/s40121-022-00620-0] [Reference Citation Analysis]
2 Delgado Rodríguez M, Domínguez García Á. Pros y contras de la vacunación frente a la enfermedad por meningococo B. Medicina Clínica 2018;150:109-13. [DOI: 10.1016/j.medcli.2017.07.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
3 Chen M, Rodrigues CMC, Harrison OB, Zhang C, Tan T, Chen J, Zhang X, Chen M, Maiden MCJ. Invasive meningococcal disease in Shanghai, China from 1950 to 2016: implications for serogroup B vaccine implementation. Sci Rep 2018;8:12334. [PMID: 30120257 DOI: 10.1038/s41598-018-30048-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
4 Stein-Zamir C, Shoob H, Abramson N, Block C, Keller N, Jaffe J, Valinsky L. Invasive meningococcal disease epidemiology and characterization of Neisseria meningitidis serogroups, sequence types, and clones; implication for use of meningococcal vaccines. Hum Vaccin Immunother 2019;15:242-8. [PMID: 30156954 DOI: 10.1080/21645515.2018.1507261] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Argante L, Abbing-Karahagopian V, Vadivelu K, Rappuoli R, Medini D. A re-assessment of 4CMenB vaccine effectiveness against serogroup B invasive meningococcal disease in England based on an incidence model. BMC Infect Dis 2021;21:1244. [PMID: 34895161 DOI: 10.1186/s12879-021-06906-x] [Reference Citation Analysis]
6 Aref HAT, Westrick S, Chou C, Worthington D, Garza K. How to inform college students about meningitis B vaccine? Comparative effectiveness of an online theory-based text and video intervention. J Am Coll Health 2022;:1-10. [PMID: 35471896 DOI: 10.1080/07448481.2022.2064713] [Reference Citation Analysis]
7 Balmer P, York LJ. Optimal use of meningococcal serogroup B vaccines: moving beyond outbreak control. Ther Adv Vaccines Immunother 2018;6:49-60. [PMID: 30182092 DOI: 10.1177/2515135518781757] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Sulis G, Horn M, Borrow R, Basta NE. A comparison of national vaccination policies to prevent serogroup B meningococcal disease. Vaccine 2022:S0264-410X(22)00568-0. [PMID: 35581099 DOI: 10.1016/j.vaccine.2022.04.101] [Reference Citation Analysis]
9 Martinón-Torres F, Taha MK, Knuf M, Abbing-Karahagopian V, Pellegrini M, Bekkat-Berkani R, Abitbol V. Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations. Pathog Glob Health 2021;:1-14. [PMID: 34569453 DOI: 10.1080/20477724.2021.1972663] [Reference Citation Analysis]
10 Luo Y, Friese OV, Runnels HA, Khandke L, Zlotnick G, Aulabaugh A, Gore T, Vidunas E, Raso SW, Novikova E, Byrne E, Schlittler M, Stano D, Dufield RL, Kumar S, Anderson AS, Jansen KU, Rouse JC. The Dual Role of Lipids of the Lipoproteins in Trumenba, a Self-Adjuvanting Vaccine Against Meningococcal Meningitis B Disease. AAPS J 2016;18:1562-75. [PMID: 27604766 DOI: 10.1208/s12248-016-9979-x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 6.8] [Reference Citation Analysis]
11 Ginsberg GM, Block C, Stein-Zamir C. Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel. Int J Public Health 2016;61:683-92. [PMID: 27105884 DOI: 10.1007/s00038-016-0821-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
12 Stawasz A, Huang L, Kirby P, Bloom D. Health Technology Assessment for Vaccines Against Rare, Severe Infections: Properly Accounting for Serogroup B Meningococcal Vaccination's Full Social and Economic Benefits. Front Public Health 2020;8:261. [PMID: 32754566 DOI: 10.3389/fpubh.2020.00261] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Riccò M, Vezzosi L, Odone A, Signorelli C. Invasive Meningococcal Disease on the Workplaces: a systematic review. Acta Biomed 2017;88:337-51. [PMID: 29083344 DOI: 10.23750/abm.v88i3.6726] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Nuttens C, Findlow J, Balmer P, Swerdlow DL, Tin Tin Htar M. Evolution of invasive meningococcal disease epidemiology in Europe, 2008 to 2017. Eurosurveillance 2022;27. [DOI: 10.2807/1560-7917.es.2022.27.3.2002075] [Reference Citation Analysis]
15 Chicuto LAD, de Moraes C, Cássio de Moraes J, Sáfadi MAP. A critical analysis of serogroup B meningococcal disease burden in Brazil (2001-2015): implications for public health decisions. Hum Vaccin Immunother 2020;16:1945-50. [PMID: 31951784 DOI: 10.1080/21645515.2019.1700710] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Flountzi A, Georgakopoulou T, Balasegaram S, Kesanopoulos K, Xirogianni A, Papandreou A, Tzanakaki G; Members of the Hellenic network for Invasive meningococcal disease. Epidemiology of invasive meningococcal disease in Greece, 2006–2016. Eur J Clin Microbiol Infect Dis 2019;38:2197-203. [DOI: 10.1007/s10096-019-03668-y] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Soysal A, Toprak DG, Türkoğlu S, Bakir M. Evaluation of the line probe assay for the rapid detection of bacterial meningitis pathogens in cerebrospinal fluid samples from children. BMC Microbiol 2017;17:14. [PMID: 28077083 DOI: 10.1186/s12866-016-0834-0] [Reference Citation Analysis]
18 MacLennan JM, Rodrigues CMC, Bratcher HB, Lekshmi A, Finn A, Oliver J, Wootton M, Ray S, Cameron C, Smith A, Heath PT, Bartolf A, Nolan T, Hughes S, Varghese A, Snape MD, Sewell R, Cunningham R, Stolton A, Kay C, Palmer K, Baxter D, Suggitt D, Zipitis CS, Pemberton N, Jolley KA, Bray JE, Harrison OB, Ladhani SN, Pollard AJ, Borrow R, Gray SJ, Trotter C, Maiden MCJ. Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the UK: comparison of UKMenCar1-4 cross-sectional survey results. Lancet Infect Dis 2021;21:677-87. [PMID: 33482143 DOI: 10.1016/S1473-3099(20)30842-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Liu Q, Liu Q, Yi J, Liang K, Hu B, Zhang X, Curtiss R 3rd, Kong Q. Outer membrane vesicles from flagellin-deficient Salmonella enterica serovar Typhimurium induce cross-reactive immunity and provide cross-protection against heterologous Salmonella challenge. Sci Rep 2016;6:34776. [PMID: 27698383 DOI: 10.1038/srep34776] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
20 Carr J, Plested E, Aley P, Camara S, Davis K, MacLennan JM, Gray S, Faust SN, Borrow R, Christensen H, Trotter C, Maiden MCJ, Finn A, Snape MD; ‘Be on the TEAM’ investigators. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents. BMJ Open 2020;10:e037358. [PMID: 33093030 DOI: 10.1136/bmjopen-2020-037358] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Pormohammad A, Lashkarbolouki S, Azimi T, Gholizadeh P, Bostanghadiri N, Safari H, Armin S, Mohtavinejad N, Fallah F. Clinical characteristics and molecular epidemiology of children with meningitis in Tehran, Iran: a prospective study. New Microbes New Infect 2019;32:100594. [PMID: 31641511 DOI: 10.1016/j.nmni.2019.100594] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Giuliani AR, Mattei A, Appetiti A, Pompei D, Di Donna F, Fiasca F, Fabiani L. Spontanuous Demand For Meningococcal B Vaccination: Effects On Appropriateness And Timing. Hum Vaccin Immunother 2018;14:2075-81. [PMID: 29927693 DOI: 10.1080/21645515.2018.1466015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
23 Rivero-Calle I, Raguindin PF, Gómez-Rial J, Rodriguez-Tenreiro C, Martinón-Torres F. Meningococcal Group B Vaccine For The Prevention Of Invasive Meningococcal Disease Caused By Neisseria meningitidis Serogroup B. Infect Drug Resist 2019;12:3169-88. [PMID: 31632103 DOI: 10.2147/IDR.S159952] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
24 Beeslaar J, Absalon J, Anderson AS, Eiden JJ, Balmer P, Harris SL, Jones TR, O'Neill RE, Pregaldien JL, Radley D, Maansson R, Ginis J, Srivastava A, Perez JL. MenB-FHbp Vaccine Protects Against Diverse Meningococcal Strains in Adolescents and Young Adults: Post Hoc Analysis of Two Phase 3 Studies. Infect Dis Ther 2020;9:641-56. [PMID: 32700260 DOI: 10.1007/s40121-020-00319-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Kuhdari P, Stefanati A, Lupi S, Valente N, Gabutti G. Meningococcal B vaccination: real-world experience and future perspectives. Pathog Glob Health 2016;110:148-56. [PMID: 27309042 DOI: 10.1080/20477724.2016.1195072] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
26 Vianzon V, Illek B, Moe GR. Effect of Vaccine-Elicited Antibodies on Colonization of Neisseria meningitidis Serogroup B and C Strains in a Human Bronchial Epithelial Cell Culture Model. Clin Vaccine Immunol 2017;24:e00188-17. [PMID: 28794055 DOI: 10.1128/CVI.00188-17] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Villena R, Safadi MAP, Valenzuela MT, Torres JP, Finn A, O'Ryan M. Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines. Hum Vaccin Immunother 2018;14:1042-57. [PMID: 29667483 DOI: 10.1080/21645515.2018.1458175] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
28 Chiu NC, Huang LM, Willemsen A, Bhusal C, Arora AK, Reynoso Mojares Z, Toneatto D. Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study. Hum Vaccin Immunother 2018;14:1075-83. [PMID: 29337653 DOI: 10.1080/21645515.2018.1425659] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]